Author(s)

Zhenqi Xu^1*, Can Gao^2*, Mengru Jian¹, Wei Du^1#

¹Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
²Department of Oncology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China.

Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.

Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

Xu, Z. , Gao, C. , Jian, M. and Du, W. (2023) Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy. Journal of Biosciences and Medicines, 11, 127-135. doi: 10.4236/jbm.2023.113013.